Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs

Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology organizations NEW YORK, ATNM, (GLOBE NEWSWIRE) Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ( Actinium or the Company ), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Jeannine Larrieux, Ph.D. has been appointed Director of Analytical Development. Dr. Larrieux will be responsible for analytical assay development, conducting biologics license application (BLA)
http://bit.ly/2i6DJ59